We conducted a multicenter , randomized , double-blind , placebo-controlled trial of caspofungin as antifungal prophylaxis in 222 adults who were in the ICU for at least 3 days , were ventilated , received antibiotics , had a central line , and had 1 additional risk factor ( parenteral nutrition , dialysis , surgery , pancreatitis , systemic steroids , or other immunosuppressants ) .